The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.
The European Commission has authorized an updated COVID-19 vaccine from Pfizer/BioNtech to be used in EU countries vaccination campaigns this autumn to target the dominant Omicron XBB.1.5 variant.
The US government awarded $1.4 billion for the development of new therapies and vaccines against COVID-19, including a $326 million to Regeneron for a next-generation antibody therapy.
Novavax s head of research and development said an updated vaccine the company is already producing is likely to be protective against other fast-growing coronavirus variants circulating in the US.